Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck Fires Research Heads

by Rick Mullin
June 24, 2013 | A version of this story appeared in Volume 91, Issue 25

Roger M. Perlmutter, the newly appointed head of Merck Research Laboratories (MRL), has unleashed what one commentator in the pharma blogosphere calls a management-level bloodbath, eliminating the heads of all of the company’s therapeutic research teams and putting in place a corps of research managers with functional responsibility across all research endeavors. “MRL’s organizational structure has been altered to simplify governance so that Merck can advance therapeutic and vaccine candidates more efficiently and focus resources on its most promising programs,” Perlmutter says. “The new design has been established to ensure that MRL leaders have the authority to take appropriate actions to facilitate rapid pipeline progress.” A spokeswoman for the company confirms published reports that a reduction in the research workforce is planned. Some cuts are coming in the near term; others will take effect over time. Merck has suffered disappointments in the clinic recently, with side effects emerging in tests of the heart drug Tredaptive earlier this year. The firm has had better news with lambrolizumab, an antibody therapy for advanced melanoma that has returned encouraging Phase I results.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.